NCT05686564No Longer Available不适用
Early Access Program for ALXN1840 in Patients With Wilson Disease
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
研究概览
简要总结
This is an open-label, single-arm, multi-center EAP, designed to provide early access to ALXN1840 for eligible patients with WD.
详细描述
To provide access to ALXN1840 treatment, an investigational medicinal product (IMP) that has not yet been granted marketing authorization, to participants who complete Studies ALXN1840-WD-205, WTX101-301, or ALXN1840-WD-302, or other studies with ALXN1840 who, in the opinion of the Treating Physician, may benefit from continued treatment with ALXN1840, and who meet the eligibility criteria described in this protocol.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 3 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •≥ 3 years of age or older at the time of providing informed consent/assent and expressed desire to continue treatment with ALXN
- •Confirmed diagnosis of WD.
- •Has completed one of the following ALXN1840 clinical studies:
- •ALXN1840-WD-205
- •ALXN1840-WD-302
- •Other ALXN1840 studies
- •In the Treating Physician's medical opinion, the potential benefits of treatment with ALXN1840 outweigh the potential risks for the participant.
- •Participant or legal representative provided informed consent/assent to be treated with ALXN1840 through this EAP.
- •Female participants of childbearing potential and male participants must follow protocol-specified-contraception guidance.
排除标准
- •Eligible for and able to participate in an Alexion-sponsored study of ALXN
- •Unwilling or unable to comply with the Treating Physician's treatment plan related to this EAP for any reason.
- •Has decompensated hepatic cirrhosis.
- •Model for End-Stage Liver Disease (MELD) score >
- •Modified Nazer Score >
- •End-stage renal disease on dialysis (chronic kidney disease stage 5 [CKD 5]) or creatinine clearance < 30 mL/min.
- •Known hypersensitivity to ALXN1840, ALXN1840 excipients, or any of the ingredients contained in ALXN
- •Women who are nursing or pregnant (or women who are planning to become pregnant during treatment with ALXN1840).
研究者
相似试验
Approved For Marketing
不适用
Early Access Program of Lazertinib in Republic of KoreaLung CancerNCT04829422Yuhan Corporation
Approved For Marketing
不适用
A Maralixibat Expanded Access Program for Patients With Cholestatic Pruritus Associated With Alagille Syndrome (ALGS)Alagille SyndromeNCT04530994Mirum Pharmaceuticals, Inc.
No Longer Available
不适用
Expanded Access to Voxelotor for Patients With Sickle Cell Disease Who Have No Alternative Treatment OptionsSickle Cell DiseaseNCT03943615Pfizer
Approved For Marketing
不适用
An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing ChemotherapyUrothelial CarcinomaNCT02589717Genentech, Inc.
No Longer Available
不适用
Early Access Program of Telaprevir With Peginterferon and Ribavirin in Chronic Hepatitis C SubjectsHepatitis CNCT01508286Janssen-Cilag International NV